OBJECTIVES: Economic modeling is an accepted tool for making formulary decisions by payers in the US. Hospital and institutional healthcare providers have expressed increased interest in using economic modeling in their decision making processes, particularly regarding potential reimbursement based on hospital-specific pricing. This study presents hospital perspective results from a revenue impact (RI) calculator component of an economic model. METHODS: An economic model was developed that investigated the RI (pharmaceutical acquisition costs minus projected reimbursement) of introducing National Comprehensive Cancer Network Category 1 recommended therapies for BRAF V600 mutated metastatic melanoma to a hospital formulary. Therapies investigated in the analysis included: dabrafenib+trametinib combination therapy, vemurafenib monotherapy, dabrafenib monotherapy, and trametinib monotherapy. The model calculated the annual pharmaceutical acquisition cost of each therapy based on recommended dosing, progression-free survival as a marker for duration of treatment, and drug pricing. Pricing data was retrieved from the Truven Health Analytics RED BOOK™ database. Acquisition costs in the model could be set to 340B, wholesale acquisition cost (WAC), or average wholesale price (AWP) values. The model used a default 30% discount compared to WAC to approximate 340B pricing. The projected reimbursement in the model uses WAC plus a modifiable 4.3% (based on the Medicare permitted reimbursement premium) for both Medicare and commercial payers. The perspective payer mix and respective reimbursement percentages can be modified by the model user. WAC was used in place of average sales price (ASP) due to the unavailability of hospital-specific ASP per therapy. RESULTS: Annual net reimbursement revenues per patient based on 340B acquisition costs were projected to be $53,270 for dabrafenib+trametinib combination, $27,043 for vemurafenib, $22,634 for dabrafenib, and $19,029 for trametinib. CONCLUSIONS: The addition of user-modifiable projected reimbursement revenue calculation is a valuable tool that expands the contribution of economic modeling to hospital formulary decision-making.